Evidence map›Paper›PMID 35876785›Full record

ArticleSchizophrenia bulletin2022

Neutrophil to Lymphocyte Ratio in Patients With a First Episode of Psychosis: A Two-Year Longitudinal Follow-up Study.

Miquel Bioque, Ana Catarina Matias-Martins, Vicent Llorca-Bofí, Gisela Mezquida, Manuel J Cuesta, Eduard Vieta, Sílvia Amoretti, Antonio Lobo, Ana González-Pinto, Carmen Moreno and 8 more

Abstract read
In one paragraph

Article in Schizophrenia bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Miquel BioqueBarcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.ORCID 0000-0001-6887-7149
Ana Catarina Matias-MartinsCentro de Investigación Biomédica en red en salud Mental, Instituto de Salud Carlos III, Barcelona, Spain.
Vicent Llorca-BofíCentro de Investigación Biomédica en red en salud Mental, Instituto de Salud Carlos III, Barcelona, Spain.ORCID 0000-0001-8467-1335
Gisela MezquidaBarcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.
Manuel J CuestaDepartment of Psychiatry, Hospital Universitario de Navarra, Pamplona (Navarra), Spain.ORCID 0000-0003-0250-5718
Eduard VietaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID 0000-0002-0548-0053
Sílvia AmorettiInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Antonio LoboCentro de Investigación Biomédica en red en salud Mental, Instituto de Salud Carlos III, Barcelona, Spain.
Ana González-PintoCentro de Investigación Biomédica en red en salud Mental, Instituto de Salud Carlos III, Barcelona, Spain.
Carmen MorenoCentro de Investigación Biomédica en red en salud Mental, Instituto de Salud Carlos III, Barcelona, Spain.
Alexandra RoldánCentro de Investigación Biomédica en red en salud Mental, Instituto de Salud Carlos III, Barcelona, Spain.
Anabel Martinez-AranInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Immaculada BaezaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Daniel BergéCentro de Investigación Biomédica en red en salud Mental, Instituto de Salud Carlos III, Barcelona, Spain.
Clemente García-RizoBarcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.
Sergi Mas HerreroDepartment of Basic Clinical Practice, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
Miquel BernardoBarcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.ORCID 0000-0001-8748-6717
2EPs GROUP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and hypothesisA pro-inflammatory phenotype has been related to psychotic disorders. The neutrophil-lymphocyte ratio (NLR) is an accessible biomarker that could be helpful to characterize this systemic inflammation state. STUDY

designThis study evaluated the NLR in a cohort of 310 subjects with a first episode of psychosis (FEP) and a matched group of 215 healthy controls, recruited in 16 Spanish centers participating in the PEPs Project. We investigated the NLR measures over 2 years in a prospective, naturalistic study. STUDY

resultsAt baseline, the FEP group showed a significant higher mean NLR compared to the control group (1.96 ± 1.11 vs 1.72 ± 0.74, P = 0.03). These ratio differences between groups grew at the 24 months follow-up visit (2.04 ± 0.86 vs 1.65 ± 0.65, P < 0.001). Within the FEP group, there were no significant differences in NLR across the follow-up visits, between genders or diagnosis groups (affective vs nonaffective). NLR values did not correlate with the Positive and Negative Symptoms Scale scores. The group of patients who did not reach remission criteria at the end of the study showed a significant higher NLR than those who remitted (2.1896 ± 0.85 vs 1.95 ± 0.87, P = 0.042). A significant correlation between antipsychotic doses and NLR was found at the two-years follow-up visit (r=0.461, P < 0.001).

conclusionsOur results highlight the existence of an underlying predisposition of FEP patients to present an increased mean NLR. The use of NLR in clinical practice could be helpful to identify this inflammatory imbalance.

Indexed as

NeutrophilsPsychotic DisordersFemaleFollow-Up StudiesHumansLymphocytesMaleProspective Studiesantipsychoticsfirst episodeinflammationneutrophil to lymphocyte ratioNLRpsychosisschizophrenia

Identifiers

PMID35876785
PMCPMC9673249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.